Results 21 to 30 of about 200,281 (336)
European Journal of Heart Failure, 2022 An algorithm for non‐invasive diagnosis of amyloid transthyretin cardiac amyloidosis (ATTR‐CA) and novel disease‐modifying therapies have prompted an active search for CA. We examined the prevalence of CA in different settings based on literature data.
A. Aimo +8 more
semanticscholar +1 more source
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis
Amyloid: Journal of Protein Folding Disorders, 2022 The recent approval of three drugs for the treatment of amyloid transthyretin (ATTR) amyloidosis, both hereditary and wild-type, has opened a new era in the care of these diseases. ATTR amyloidosis is embedded in its pathophysiology, and the drugs target
Y. Ando +13 more
semanticscholar +1 more source
A prospective study of nutritional status in immunoglobulin light chain amyloidosis
Haematologica, 2013 Weight loss is common in systemic immunoglobulin light chain amyloidosis but there are limited data on the impact of nutritional status on outcome.
Prayman T. Sattianayagam +12 more
doaj +1 more source
Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection? [PDF]
, 2012 Background: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Amann, Kerstin Ute +7 more
core +2 more sources
Transthyretin cardiac amyloidosis
Cardiovascular Research, 2022 Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and ...
A. Porcari, M. Fontana, J. Gillmore
semanticscholar +1 more source
Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Advancement in the diagnosis and treatment of transthyretin amyloid cardiomyopathy has made great strides in recent years. Novel therapeutics for transthyretin amyloidosis such as tafamidis, patisiran, and inotersen have shown significant benefits in a ...
Hongya Chen +6 more
doaj +1 more source
Blood Cancer Journal, 2022 Effective systemic therapies suppress toxic light chain production leading to an increased proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end-stage renal disease.
Andrea Havasi +21 more
doaj +1 more source
Abnormal Myocardial Blood Flow Reserve Observed in Cardiac Amyloidosis [PDF]
, 2016 We performed real-time myocardial contrast echocardiography on a patient with cardiac amyloidosis and previous normal coronary angiography presenting with atypical chest pain to assess myocardial blood flow reserve (MBFR).
Greaves, K, Nam, MC, Nel, K, Senior, R
core +1 more source
The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa [PDF]
, 2016 Transthyretin (TTR) pV142I (rs76992529-A) is one of the 113 variants in the human TTR gene associated with systemic amyloidosis. It results from a G to A transition at a CG dinucleotide in the codon for amino acid 122 of the mature protein (TTR V122I ...
Alexander, Alice A +10 more
core +1 more source
Amyloid: Journal of Protein Folding Disorders, 2020 The ISA Nomenclature Committee met electronically before and directly after the XVII ISA International Symposium on Amyloidosis, which, unfortunately, had to be virtual in September 2020 due to the ongoing COVID-19 pandemic instead of a planned meeting ...
M. Benson +7 more
semanticscholar +1 more source